KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) EBT Margin (2016 - 2025)

Gilead Sciences (GILD) has disclosed EBT Margin for 17 consecutive years, with 26.22% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 241.0% year-over-year to 26.22%, compared with a TTM value of 33.27% through Dec 2025, up 3087.0%, and an annual FY2025 reading of 33.27%, up 3087.0% over the prior year.
  • EBT Margin was 26.22% for Q4 2025 at Gilead Sciences, down from 46.85% in the prior quarter.
  • Across five years, EBT Margin topped out at 46.85% in Q3 2025 and bottomed at 67.1% in Q1 2024.
  • Average EBT Margin over 5 years is 22.07%, with a median of 26.85% recorded in 2022.
  • The sharpest move saw EBT Margin plummeted -8756bps in 2024, then soared 9183bps in 2025.
  • Year by year, EBT Margin stood at 10.48% in 2021, then surged by 162bps to 27.49% in 2022, then dropped by -15bps to 23.24% in 2023, then grew by 23bps to 28.63% in 2024, then fell by -8bps to 26.22% in 2025.
  • Business Quant data shows EBT Margin for GILD at 26.22% in Q4 2025, 46.85% in Q3 2025, and 34.3% in Q2 2025.